Purchase Order 75N93020P00194

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $14,023.75 on July 22, 2020, for Brilliant Violet anti-human CD8A RPA-T8 and Brilliant Violet anti-human CD154 antibody clone 24-31 reagents to support COVID-19 research. Performance occurs in San Diego, California, with completion targeted for August 21, 2020. The order is firm fixed-price with no small business set-aside.</p>

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $8,377.50 to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The contract is for the delivery of &quot;Brilliant Violet Anti-Human Antibodies&quot; to support the agency's research efforts. Biolegend, Inc. is a subsidiary of the parent company Revvity Inc. This contract...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $25,000 purchase order to Biolegend, Inc., a medical division of Revvity Inc., to deliver Brilliant Violet 650TM anti-human CD197. The firm fixed price contract runs from September 20, 2023 through December 29, 2023 for the provision of this product to support NIH research efforts. No major subcontractors or set aside designations were identified. Biolegend...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed-price purchase order valued at $21,863.25 to Biolegend, Inc. for BIOLEGEND TOTALSEQ ANTIBODIES. No set-aside designation was used. Performance will occur in San Diego, California with a completion date of May 7, 2024. Biolegend, Inc. is a subsidiary of Revvity Inc.'s Medical Imaging, LLC division. The award is likely associated with research efforts...

This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH), to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The $16,199.95 contract is for the delivery of BIOLEGEND antibodies to support NIAID's research initiatives, which may include studies related to COVID-19, immunology, and other disease areas. The contract does not...

This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....